An Updated Economic Analysis Of Treatment Costs Related To Parenteral Nutrition

Published May 12, 2014
Deerfield, IL, USA - Patients with dysfunctional gastrointestinal tracts receive parenteral nutrition (PN) to help meet their nutrition requirements. Parenteral nutrition may be administered through a variety of techniques including premixed or pharmacy compounded solutions. The decision about PN delivery choice can be complex and there are no specific guidelines advising an optimal method. Researchers at Baxter Healthcare Corporation and Premier Research Services sought to build on published evidence through a retrospective analysis of Premier’s Hospital Database by comparing outcomes in critically ill adult patients receiving premixed versus compounded PN. Specifically, they compared patients’ total health care costs, length of hospital stay, infectious complications, and hospital readmission rates. After adjusting for confounding variables, they found patients receiving premixed PN incurred nine percent less in total costs, 2.6 percent fewer days in the hospital, and no significant differences for infectious complications or 30-day readmission. This study aimed to provide a more comprehensive PN economic analysis than previous evaluations. The researchers noted that, excluding overall costs, patients experienced similar outcomes irrespective of the PN preparation delivery chosen, therefore, future studies need to further explore cost drivers. Study lead, Gary Zaloga, MD, Senior Medical Director at Baxter, states, “Given this information, clinicians should continue to focus on best practices that will lead to improve patient outcomes and a reduction in financial burden.” The full study, “A Retrospective, Observational Study of Patient Outcomes for Critically Ill Patients Receiving Parenteral Nutrition,” is published in Value in Health.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision-makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Launches New Content on Whole Health

Sep 23, 2025

ISPOR announced that it has launched new website content on whole health, a topic of increasing importance as health systems across the globe grapple with providing the best possible healthcare to patients within constrained budgets.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×